These Analysts Increase Their Forecasts On Immunovant After Q4 Results

Benzinga05-22 00:07

Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.

The company reported a quarterly loss of 73 cents per share, falling short of the 60 cents consensus estimate.

Research and development spending rose to $142.3 million for the quarter, driven by IMVT‑1402 trial activity and $39 million in costs tied to discontinuing batoclimab. Non‑GAAP R&D expenses for the full fiscal year reached $426.9 million, up from $333.9 million the prior year.

Immunovant shares fell 5% to trade at $33.76 on Thursday.

These analysts made changes to their price targets on Immunovant following earnings announcement.

HC Wainwright & Co. analyst Douglas Tsao maintained Immunovant with a Buy and raised the price target from $35 to $40.
B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $32 to $43.

Considering buying IMVT stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2637135895?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 00:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637135895","market":"us","top_or_hot":-1,"title":"These Analysts Increase Their Forecasts On Immunovant After Q4 Results","media":"Benzinga","content":"<html><body><p><strong>Immunovant Inc </strong>(NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.</p>\n<p>The company reported a quarterly loss of 73 cents per share, falling short of the 60 cents consensus estimate.</p>\n<p>Research and development spending rose to $142.3 million for the quarter, driven by IMVT‑1402 trial activity and $39 million in costs tied to discontinuing batoclimab. Non‑GAAP R&amp;D expenses for the full fiscal year reached $426.9 million, up from $333.9 million the prior year.</p>\n<p>Immunovant shares fell 5% to trade at $33.76 on Thursday.</p>\n<p>These analysts made changes to their price targets on Immunovant following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Douglas Tsao maintained Immunovant with a Buy and raised the price target from $35 to $40.</li>\n<li>B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $32 to $43.</li>\n</ul>\n<p><strong>Considering buying IMVT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"453\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/21104838/image-564-1024x453.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/21104838/image-564-1024x453.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/21104838/image-564-300x133.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/21104838/image-564-768x340.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/21104838/image-564.png 1212w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Increase Their Forecasts On Immunovant After Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Increase Their Forecasts On Immunovant After Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-05-22 00:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Immunovant Inc </strong>(NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.</p>\n<p>The company reported a quarterly loss of 73 cents per share, falling short of the 60 cents consensus estimate.</p>\n<p>Research and development spending rose to $142.3 million for the quarter, driven by IMVT‑1402 trial activity and $39 million in costs tied to discontinuing batoclimab. Non‑GAAP R&amp;D expenses for the full fiscal year reached $426.9 million, up from $333.9 million the prior year.</p>\n<p>Immunovant shares fell 5% to trade at $33.76 on Thursday.</p>\n<p>These analysts made changes to their price targets on Immunovant following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Douglas Tsao maintained Immunovant with a Buy and raised the price target from $35 to $40.</li>\n<li>B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $32 to $43.</li>\n</ul>\n<p><strong>Considering buying IMVT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"453\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/21104838/image-564-1024x453.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/21104838/image-564-1024x453.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/21104838/image-564-300x133.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/21104838/image-564-768x340.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/21104838/image-564.png 1212w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52723743/these-analysts-increase-their-forecasts-on-immunovant-after-q4-results","article_id":"2637135895","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637135895","pubTimestamp":1779379634,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&amp;D expenses rose to $142.3 million. Analysts adjust price targets.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念","IMVT":"Immunovant, Inc."},"translate_title":"这些分析师在第四季度业绩公布后上调了对Immunovant的预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMVT":1},"content_text":"Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.\nThe company reported a quarterly loss of 73 cents per share, falling short of the 60 cents consensus estimate.\nResearch and development spending rose to $142.3 million for the quarter, driven by IMVT‑1402 trial activity and $39 million in costs tied to discontinuing batoclimab. Non‑GAAP R&D expenses for the full fiscal year reached $426.9 million, up from $333.9 million the prior year.\nImmunovant shares fell 5% to trade at $33.76 on Thursday.\nThese analysts made changes to their price targets on Immunovant following earnings announcement.\n\nHC Wainwright & Co. analyst Douglas Tsao maintained Immunovant with a Buy and raised the price target from $35 to $40.\nB of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $32 to $43.\n\nConsidering buying IMVT stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637135895","isCrawlerRequest":true}